Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes
Novo Nodisk's CSO says FDA approval of extended half-life Factor VIII Esperoct treatment for people with hemophilia A will give more choice to those patients and "effectively completes" the Danish group's hitherto R&D efforts based on clotting factor deficiencies.
Pioneering Gyroscope Therapeutics Aims To Develop One-Time Gene Therapy For AMD
Gyroscope Therapeutics, which aims to develop genetically defined therapies for a range of eye diseases, has begun dosing in a Phase I/II clinical trial in dry age-related macular degeneration using its lead candidate.
Troubled Realm Therapeutics Selling Assets, Delisting From London AIM
US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.
Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
US Rights Deal Will Make Proleukin Clinigen's Biggest Product
Clinigen's planned purchase of US rights to Proleukin will give it global ownership of the IL-2 drug.
Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.